Form 4: Heron Therapeutics CEO Converts RSUs to Common Stock

Heron Therapeutics CEO Craig Collard converted 34,789 restricted stock units into common stock, increasing his direct ownership.

Summary

• Craig A. Collard, Chief Executive Officer and Director of HERON THERAPEUTICS, INC. (HRTX), reported a transaction on January 31, 2026.
• Collard acquired 34,789 shares of common stock through the conversion of restricted stock units (RSUs).
• Following this transaction, Collard directly beneficially owns 571,710 shares of common stock.
• The transaction involved the disposition of 34,789 derivative securities in the form of restricted stock units.
• After the conversion, Collard directly beneficially owns 417,464 restricted stock units.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The restricted stock units vest in 16 equal installments, with vesting having commenced one quarter after the grant date of January 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine compensation event. The conversion of RSUs to common stock increases the CEO's direct equity stake, which can be seen as a positive signal of alignment with shareholder interests, though it is a standard part of executive compensation.

Positives

• The conversion of restricted stock units into common stock increases the CEO's direct ownership in the company, aligning his interests more closely with shareholders.

Industry Context

StockSavvy.ai notes that the conversion of restricted stock units (RSUs) into common stock is a routine event in executive compensation, reflecting the vesting of previously granted equity awards. This type of transaction is common across various industries as a mechanism to incentivize and retain key management personnel.

Stakeholder Impact

• Shareholders may view the increased direct ownership by the CEO as a positive sign of management's commitment and alignment with long-term company performance.

Next Steps

• The remaining 417,464 restricted stock units held by Craig A. Collard will continue to vest in 16 equal installments, as per the original grant terms beginning one quarter after January 31, 2025.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the conversion of restricted stock units into common stock as part of executive compensation. It does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as this event alone is unlikely to significantly alter the investment thesis.

Keywords

HERON THERAPEUTICS, HRTX, Craig Collard, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Common Stock, Executive Compensation